Merck & Co Inc (MRK): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Merck ( MRK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.7%. By the end of trading, Merck rose $0.53 (1.1%) to $49.32 on average volume. Throughout the day, 16,301,817 shares of Merck exchanged hands as compared to its average daily volume of 13,529,600 shares. The stock ranged in a price between $48.63-$49.44 after having opened the day at $48.86 as compared to the previous trading day's close of $48.79. Other companies within the Drugs industry that increased today were: Oramed Pharmaceuticals ( ORMP), up 49.0%, Amarin Corporation ( AMRN), up 25.5%, AVANIR Pharmaceuticals ( AVNR), up 19.7% and Ariad Pharmaceuticals ( ARIA), up 16.5%.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $142.9 billion and is part of the health care sector. The company has a P/E ratio of 32.8, above the S&P 500 P/E ratio of 17.7. Shares are up 19.2% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 43.4%, Celator Pharmaceuticals ( CPXX), down 13.5%, Ocera Therapeutics ( OCRX), down 13.1% and Idera Pharmaceuticals ( IDRA), down 8.5% , were all laggards within the drugs industry with Actavis ( ACT) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts